Hemoglobins

Five-year-old battling a critical illness helps spread awareness about sickle cell disease

Retrieved on: 
Saturday, June 19, 2021
Branches of biology, Hemoglobins, Medical specialties, Clinical medicine, Health in Africa, Hematopathology, Sickle cell disease, Red blood cell, Sickle cell trait, Fetal hemoglobin

When Amina was only a few days old, she was diagnosed with sickle cell disease (SCD) a genetic red blood cell disorder affecting hemoglobin.

Key Points: 
  • When Amina was only a few days old, she was diagnosed with sickle cell disease (SCD) a genetic red blood cell disorder affecting hemoglobin.
  • "If you have sickle cell disease, your red blood cells are crescent or 'sickle' shaped.
  • According to the Centers for Disease Control and Prevention (CDC ), sickle cell disease currently affects approximately 100,000 people in the U.S. predominantly certain ethnic groups.
  • If you want to help your local chapter or find out how to refer a child battling sickle cell disease for a life-changing wish, visit wish.org .

Imara Announces Recipients of the Second Annual Real Impact Grants Program to Support People Affected by Rare Genetic Blood Disorders

Retrieved on: 
Thursday, June 17, 2021
Health in Africa, Clinical medicine, Medical specialties, Sickle Cell Disease Association of America, Sickle cell disease, Branches of biology, Hemoglobins

Crescent Foundation is very appreciative to receive funding through the Imara Real Impact Grant program to help support our One Gene, One Life program, said Kyle Smith, CEO and Co-Founder at the Crescent Foundation.

Key Points: 
  • Crescent Foundation is very appreciative to receive funding through the Imara Real Impact Grant program to help support our One Gene, One Life program, said Kyle Smith, CEO and Co-Founder at the Crescent Foundation.
  • The One Gene, One Life program focuses on highlighting the needs of the sickle cell disease community to future medical practitioners.
  • Real Impact grant recipients include:
    Sickle Cell Disease Association of America Inc: Miami-Dade County Chapter, Inc.
    Sickled Not Broken Foundation of NV, Inc.
  • Supporters of Families with Sickle Cell Disease, Inc.
    Cayenne Wellness Center | Sickle Cell Education, Support, and Advocacy
    Sickle Cell Foundation of Georgia, Inc.

Newborn Screening Test for Sickle Cell Disease Now Supported by Gazelle 8-Minute, Point-of-Care Diagnostic

Retrieved on: 
Monday, June 14, 2021
Health, Consumer, Technology, Other Health, Mobile, Wireless, Baby, Maternity, Hardware, Medical specialties, Branches of biology, Clinical medicine, Hemoglobins, Health in Africa, Blood disorders, Hematopathology, Sickle cell disease, Respiratory physiology, Hematologic disease, Hemoglobinopathy, Scd

The upgrade, free to those with the Gazelle device, also includes printing enhancements and a variety of ease-of-use features.

Key Points: 
  • The upgrade, free to those with the Gazelle device, also includes printing enhancements and a variety of ease-of-use features.
  • Sickle cell disease (SCD) is one of the most common and severe of all inherited hematological disorders, causing substantial morbidity and mortality worldwide.
  • According to the Sickle Cell Disease Foundation, SCD is responsible for between 5% and 16% of all infant deaths in sub-Saharan Africa.
  • Hemex improvements enable the Gazelle test to identify these low levels for sickle cell disease and trait, Barts, and other important hemoglobinopathies at birth, continued Dr. Obaro.

Agios Announces Updated Data from ACTIVATE and ACTIVATE-T Phase 3 Studies of Mitapivat in Pyruvate Kinase (PK) Deficiency at the European Hematology Association Virtual Congress

Retrieved on: 
Friday, June 11, 2021
Branches of biology, Metabolism, Natural sciences, Chemistry, Respiratory physiology, Hemoglobins, Pyruvate kinase, Enzyme, Pyruvic acid, Kinase

Data from the studies will be featured in oral presentations on Tuesday, June 15, at the European Hematology Association (EHA) Virtual Congress.

Key Points: 
  • Data from the studies will be featured in oral presentations on Tuesday, June 15, at the European Hematology Association (EHA) Virtual Congress.
  • Mitapivat is a first-in-class, investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated pyruvate kinase R (PKR) enzymes.
  • Mitapivat demonstrated a sustained, statistically significant increase in hemoglobin in patients with PK deficiency who are not regularly transfused.
  • 40 percent (n=16) of patients randomized to mitapivat achieved a hemoglobin response, compared to 0 patients randomized to placebo (2-sided p

Global Sickle Cell Anemia Market Spotlight 2021: Global Blood Therapeutics Leads Industry Sponsors - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 8, 2021
Health, Biotechnology, Blood, Medical specialties, Branches of biology, Hemoglobins, Hematopathology, Health in Africa, Anemias, Transfusion medicine, Sickle cell disease, Fetal hemoglobin, Hemoglobin C, Sickle cell trait

Using an estimated global prevalence of 0.04%, the publisher approximated that there were 3.3 million prevalent cases of sickle cell anemia worldwide in 2019.

Key Points: 
  • Using an estimated global prevalence of 0.04%, the publisher approximated that there were 3.3 million prevalent cases of sickle cell anemia worldwide in 2019.
  • The approved drugs in the sickle cell anemia space target selectins, fetal hemoglobin, nicotinamide adenine dinucleotide, and hemoglobin.
  • Global Blood Therapeutics has the highest number of completed clinical trials for sickle cell anemia, with 10 trials.
  • Global Blood Therapeutics leads industry sponsors with the highest overall number of clinical trials for sickle cell anemia, followed by Novartis

Imara to Present Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress

Retrieved on: 
Friday, June 4, 2021
Clinical medicine, Medical specialties, Branches of biology, Health in Africa, Mediterranean, Thalassemia, Sickle cell disease, Beta thalassemia, Hemoglobins

ET (9:00 a.m. CEST)and a copy of the presentation will also be available on the Investors section of the Imara website .

Key Points: 
  • ET (9:00 a.m. CEST)and a copy of the presentation will also be available on the Investors section of the Imara website .
  • Increased levels of HbF in red blood cells have been demonstrated to improve symptomology and lower disease burden in patients with sickle cell disease and patients with beta-thalassemia.
  • Imara is currently advancing IMR-687, a highly selective, potent small molecule inhibitor of PDE9 that is an oral, once-a-day, potentially disease-modifying treatment for sickle cell disease and beta-thalassemia.
  • These statements include, but are not limited to, statements relating to the Companys plans to present data on the Phase 2a and OLE clinical trials of IMR-687 in patients with sickle cell disease at the EHA Annual Congress and the quality of such data.

CHOP Researchers Develop Proof-of-Concept Treatment that Elevates Both Adult and Fetal Hemoglobin

Retrieved on: 
Tuesday, June 1, 2021
Hemoglobins, Medical specialties, Hematology, Branches of biology, Hemoglobin A, Fetal hemoglobin, Thalassemia, Beta thalassemia, Hemoglobin variants, Hemoglobinopathy

PHILADELPHIA, June 1, 2021 /PRNewswire/ --Researchers at Children's Hospital of Philadelphia (CHOP) have developed a proof-of-concept treatment for blood disorders like sickle cell disease and beta-thalassemia that could raise hemoglobin levels by activating production of both fetal and adult hemoglobin.

Key Points: 
  • PHILADELPHIA, June 1, 2021 /PRNewswire/ --Researchers at Children's Hospital of Philadelphia (CHOP) have developed a proof-of-concept treatment for blood disorders like sickle cell disease and beta-thalassemia that could raise hemoglobin levels by activating production of both fetal and adult hemoglobin.
  • Using a viral vector engineered to reactivate fetal hemoglobin production, suppress mutant hemoglobin, and supply functional adult hemoglobin, the researchers developed an approach that could produce more hemoglobin through a single vector.
  • In utero, the gamma-globin gene produces fetal hemoglobin, but after birth, this gene is switched off and the beta-globin gene is turned on, producing adult hemoglobin.
  • By elevating both fetal and functional adult hemoglobin, the vector was able to induce more functional hemoglobin production than that of a vector expressing beta-globin alone.

Vertex and CRISPR Therapeutics to Present New Clinical Data on Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001™ For Severe Hemoglobinopathies at the Annual European Hematology Association Virtual Congress

Retrieved on: 
Wednesday, May 12, 2021
Branches of biology, Biology, Hemoglobins, Life sciences, Biotechnology, Genetic engineering, Respiratory physiology, Emerging technologies, CRISPR Therapeutics, CRISPR, Fetal hemoglobin

HbF is a form of the oxygen-carrying hemoglobin that is naturally present at birth, which then switches to the adult form of hemoglobin.

Key Points: 
  • HbF is a form of the oxygen-carrying hemoglobin that is naturally present at birth, which then switches to the adult form of hemoglobin.
  • Patients undergoing stem cell transplants may also encounter side effects (ranging from mild to severe) that are unrelated to the administration of CTX001.
  • Under a recently amended collaboration agreement, Vertex will lead global development, manufacturing and commercialization of CTX001 and split program costs and profits worldwide 60/40 with CRISPR Therapeutics.
  • CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Insights on the Hemoglobin Testing Global Market to 2026 - by Product Type, Technology, End-user and Region - ResearchAndMarkets.com

Retrieved on: 
Tuesday, May 11, 2021
Science, Health, Other Science, Other Health, Hemoglobins, Branches of biology, Blood, Hematology, Anemia, Red blood cell, Hemoglobin D-Punjab, Hemoglobin C

b'The "Hemoglobin Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe global hemoglobin testing market exhibited moderate growth during 2015-2020.

Key Points: 
  • b'The "Hemoglobin Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe global hemoglobin testing market exhibited moderate growth during 2015-2020.
  • Looking forward, the publisher expects the global hemoglobin testing market to grow at a CAGR of 6.80% during 2021-2026.\nA hemoglobin test measures the count of red blood cells (RBC) or the level of hemoglobin in the blood.
  • The key end users of hemoglobin testing market are medical laboratories, hospitals and research centers.\nAn increasing prevalence of chronic disorders such as anemia and diabetes represent a key factor driving the global hemoglobulin testing market.
  • are also projected to drive the global hemoglobin testing market in the coming years.\n'

NONIN MEDICAL’S CO-PILOT RECOGNIZED IN FAST COMPANY’S 2021 WORLD CHANGING IDEAS AWARDS

Retrieved on: 
Monday, May 10, 2021
Medical specialties, Medicine, Clinical medicine, Hemoglobins, Cardiology, Medical monitoring, Pulse oximetry, Respiratory physiology, Methemoglobin, Monitoring, Carboxyhemoglobin

b'MINNEAPOLIS, May 10, 2021 (GLOBE NEWSWIRE) -- Nonin Medical, a global leader in noninvasive medical monitoring and the manufacturer of the CO-Pilot\xe2\x84\xa2 Wireless Handheld Multi-Parameter System, received an honorable mention in Fast Company\xe2\x80\x99s 5th annual World Changing Ideas Awards in the health category.

Key Points: 
  • b'MINNEAPOLIS, May 10, 2021 (GLOBE NEWSWIRE) -- Nonin Medical, a global leader in noninvasive medical monitoring and the manufacturer of the CO-Pilot\xe2\x84\xa2 Wireless Handheld Multi-Parameter System, received an honorable mention in Fast Company\xe2\x80\x99s 5th annual World Changing Ideas Awards in the health category.
  • It offers reliable readings to allow for improved first responder patient care or any emergency setting outside of the hospital.
  • The CO-Pilot simultaneously tracks patient pulse oximetry (SpO2), pulse rate, carboxyhemoglobin (COHb) and methemoglobin (MetHb); cerebral and tissue oximetry (rSO2) can be measured using an additional sensor.\nThe World Changing Ideas Awards recognize innovators in categories such as Health & Wellness and AI & Data.
  • To learn more, visit nonin.com .\nABOUT THE WORLD CHANGING IDEAS AWARDS:\nWorld Changing Ideas is one of Fast Company\xe2\x80\x99s major annual awards programs and is focused on social good, seeking to elevate finished products and brave concepts that make the world better.